A patent law change pushed by the pharmaceutical industry could cost federal health-care programs $1.3 billion over a decade by delaying new generic drugs, the Congressional Budget Office estimates.
Sourced through Scoop.it from: www.wsj.com
Kenneth Carnesi holds a Juris Doctor degree from New York Law School and a Professional Certificate in International Banking from Harvard Law School. Kenneth Carnesi is the Director of Operations and Government Sales at Anaptyx LLC and sits on the Boards of The Lazarus Organization, Monkeetech LLC and MG Madison Phillips, Inc. Mr. Carnesi has also founded CICG - Carnesi International Consulting Group, a company specializing in strategy consulting to small to mid-size businesses.
Kenneth Carnesi 
Leave a comment